Mr. Vladimir A. Makatsaria has been the Chief Executive Officer and Director at LivaNova PLC since March 01, 2024. He is a Non-Executive Director of the Health Products Regulatory Authority Board in Irelan...

리더십 팀

이름	위치	테뉴어	보상	소유권
Alex Shvartsburg	Chief Financial Officer	3.6yrs	US$2.77m	0.035% $ 1.0m
Michael Hutchinson	Senior VP	1.6yrs	US$2.07m	0.0042% $ 125.3k
Trui Hebbelinck	Chief Human Resources Officer	5.3yrs	US$1.78m	0.025% $ 755.5k
Vladimir Makatsaria	CEO & Director	less than a year	데이터 없음	데이터 없음
Badri Amurthur	Chief Technology Officer	less than a year	데이터 없음	데이터 없음
Lindsey Little	Senior Director of Investor Relations	no data	데이터 없음	데이터 없음
Deanna Wilke	Vice President of Corporate Communications	no data	데이터 없음	데이터 없음
Matthew Dodds	Senior Vice President of Corporate Development & IT	6.4yrs	데이터 없음	데이터 없음
Paul Buckman	President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement	no data	데이터 없음	데이터 없음
Stephanie Bolton	President of Global Epilepsy	4.4yrs	데이터 없음	0.018% $ 524.3k
Ahmet Tezel	Chief Innovation Officer	less than a year	데이터 없음	데이터 없음
John Webb	Vice President of Sleep Apnea and Epilepsy	no data	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: LIVN 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vladimir Makatsaria	CEO & Director	less than a year	데이터 없음	데이터 없음
Todd Schermerhorn	Independent Non-Executive Director	3.5yrs	US$270.00k	0.011% $ 332.2k
Peter Wilver	Independent Director	2yrs	US$263.00k	0.0069% $ 204.5k
William Kozy	Chairman of Board	6yrs	US$3.34m	0.051% $ 1.5m
Sharon O'Kane	Independent Non-Executive Director	8.7yrs	US$281.43k	0.018% $ 520.4k
Stacy Seng	Independent Non-Executive Director	5yrs	US$260.00k	0.016% $ 479.4k
Francesco Bianchi	Independent Non-Executive Director	8.7yrs	US$263.00k	0.019% $ 563.1k
J. Barry	Independent Director	less than a year	US$117.88k	데이터 없음
Brooke Story	Independent Director	1.8yrs	US$248.00k	0.0064% $ 190.6k

3.5yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: LIVN 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

LivaNova 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Independent Director notifies of intention to sell stock

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

Chief Financial Officer exercised options and sold US$353k worth of stock

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Recent updates

LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024

Daniel Jeffrey Moore Resigns as Director of LivaNova PLC

Is LivaNova PLC (NASDAQ:LIVN) Trading At A 31% Discount?

LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients

Independent Director notifies of intention to sell stock

LivaNova: Focus Is Paying Off

Now 21% undervalued

LivaNova PLC Provides Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer

LivaNova PLC, Annual General Meeting, Jun 11, 2024

These Return Metrics Don't Make LivaNova (NASDAQ:LIVN) Look Too Strong

Chief Financial Officer exercised options and sold US$353k worth of stock

LivaNova PLC to Report Q1, 2024 Results on May 01, 2024

Now 21% overvalued after recent price rise

LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% overvalued after recent price rise

Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023

LivaNova PLC Announces CEO Changes, Effective on March 1, 2024

Is It Time To Consider Buying LivaNova PLC (NASDAQ:LIVN)?

A Look At The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024

LivaNova PLC's (NASDAQ:LIVN) Business And Shares Still Trailing The Industry

LivaNova (NASDAQ:LIVN) Could Be At Risk Of Shrinking As A Company

We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve

New minor risk - Earnings quality

Livanova plc Provides Revenue Guidance for the Full-Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

At US$47.94, Is LivaNova PLC (NASDAQ:LIVN) Worth Looking At Closely?

LivaNova PLC Announces Board Changes

Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 44%?

Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023

LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023

LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark

Price target increased by 7.7% to US$65.33

LivaNova PLC Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Capital Allocation Trends At LivaNova (NASDAQ:LIVN) Aren't Ideal

Should You Investigate LivaNova PLC (NASDAQ:LIVN) At US$51.43?

LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023

LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study

An Intrinsic Calculation For LivaNova PLC (NASDAQ:LIVN) Suggests It's 37% Undervalued

LivaNova PLC Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.1% to US$62.25

Investors Could Be Concerned With LivaNova's (NASDAQ:LIVN) Returns On Capital

CEO & Director exercised options and sold US$432k worth of stock

What Does LivaNova PLC's (NASDAQ:LIVN) Share Price Indicate?

CEO & Director exercised options and sold US$805k worth of stock

Full year 2022 earnings released: US$1.61 loss per share (vs US$2.68 loss in FY 2021)

Estimating The Fair Value Of LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures

LivaNova Launches SenTiva DUO

LivaNova PLC to Report Q4, 2022 Results on Feb 22, 2023

Returns At LivaNova (NASDAQ:LIVN) Are On The Way Up

Forecast breakeven date pushed back to 2023

Forecast breakeven date pushed back to 2023

Price target decreased to US$73.71

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

LivaNova PLC Announces Management Changes

Is There Now An Opportunity In LivaNova PLC (NASDAQ:LIVN)?

LivaNova Loses Profit Momentum On Higher R&D Expense

Price target decreased to US$79.57

LivaNova PLC (NASDAQ:LIVN) Shares Could Be 30% Below Their Intrinsic Value Estimate

FDA labels recall of blood bypass pump systems by LivaNova as most serious

LivaNova PLC to Report Q3, 2022 Results on Nov 02, 2022

Now 21% undervalued after recent price drop